NCT00992511View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 14, 2009

Primary Completion Date

November 9, 2010

Study Completion Date

November 9, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

GSK investigational vaccine GSK2340272A

One intramuscular injection of initial process-manufactured GSK2340272A vaccine

BIOLOGICAL

GSK investigational vaccine GSK2340272A

Two intramuscular injections of initial process-manufactured GSK2340272A vaccine

BIOLOGICAL

GSK investigational vaccine GSK2340272A

One intramuscular injection of new process-manufactured GSK2340272A vaccine

BIOLOGICAL

GSK investigational vaccine GSK2340272A

Two intramuscular injections of new process-manufactured GSK2340272A vaccine

Trial Locations (4)

01067

GSK Investigational Site, Dresden

01307

GSK Investigational Site, Dresden

09599

GSK Investigational Site, Freiberg

04103

GSK Investigational Site, Leipzig

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00992511 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes | Biotech Hunter | Biotech Hunter